Total Payments
$99,250
2024 Payments
$30,474
Companies
31
Transactions
746
Medicare Patients
313
Medicare Billing
$38,239
Payment Breakdown by Category
Other$73,809 (74.4%)
Food & Beverage$15,191 (15.3%)
Travel$10,073 (10.1%)
Education$176.59 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $73,809 | 25 | 74.4% |
| Food and Beverage | $15,191 | 697 | 15.3% |
| Travel and Lodging | $10,073 | 21 | 10.1% |
| Education | $176.59 | 3 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $62,903 | 56 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $15,280 | 29 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $9,233 | 29 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,245 | 240 | $0 (2024) |
| ABBVIE INC. | $2,938 | 138 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $956.82 | 62 | $0 (2024) |
| Janssen Biotech, Inc. | $750.51 | 25 | $0 (2024) |
| RedHill Biopharma Inc. | $548.18 | 31 | $0 (2024) |
| QOL Medical, LLC | $517.70 | 17 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $507.31 | 16 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,474 | 173 | GENZYME CORPORATION ($18,611) |
| 2023 | $50,449 | 184 | GENZYME CORPORATION ($36,405) |
| 2022 | $14,408 | 164 | GENZYME CORPORATION ($7,887) |
| 2021 | $2,592 | 139 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($894.17) |
| 2020 | $1,313 | 85 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($461.56) |
| 2019 | $14.65 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($14.65) |
All Payment Transactions
746 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $860.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $9.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/27/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/26/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $125.00 | General |
| 10/26/2024 | PFIZER INC. | XELJANZ (Drug), INFLECTRA, ABRILADA | Food and Beverage | In-kind items and services | $33.09 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/21/2024 | PFIZER INC. | XELJANZ (Drug), INFLECTRA, ABRILADA | Food and Beverage | In-kind items and services | $35.51 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/17/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,720.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $218.23 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | Cash or cash equivalent | $150.53 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Gastroenterology | ||||||
| 09/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Travel and Lodging | Cash or cash equivalent | $81.84 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: Gastroenterology | ||||||
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Gastroenterology | ||||||
| 09/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Gastroenterology | ||||||
| 08/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Gastroenterology | ||||||
| 08/26/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $27.18 | General |
| Category: Neuroscience | ||||||
| 08/23/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $135.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/22/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.04 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: Gastroenterology | ||||||
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $1.47 | General |
| Category: IMMUNOLOGY | ||||||
| 08/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $0.37 | General |
| Category: IMMUNOLOGY | ||||||
| 08/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $28.70 | General |
| Category: IMMUNOLOGY | ||||||
| 08/12/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $24.33 | General |
| Category: GI | ||||||
| 08/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/12/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $2.55 | General |
| Category: INTERNAL MEDICINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 114 | 146 | $30,640 | $12,203 |
| 2022 | 3 | 80 | 126 | $26,405 | $11,116 |
| 2021 | 5 | 108 | 140 | $53,910 | $13,659 |
| 2020 | 1 | 11 | 13 | $3,120 | $1,260 |
Total Patients
313
Total Services
425
Medicare Billing
$38,239
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 65 | $11,375 | $4,920 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 34 | $8,160 | $3,686 | 45.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $6,660 | $2,519 | 37.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $3,965 | $944.10 | 23.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 15 | 16 | $480.00 | $134.40 | 28.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 39 | 77 | $13,475 | $6,020 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 23 | 31 | $7,440 | $3,227 | 43.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $5,490 | $1,868 | 34.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 59 | $10,325 | $4,914 | 47.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 23 | 31 | $7,440 | $3,527 | 47.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $5,550 | $1,977 | 35.6% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 16 | 16 | $24,800 | $1,645 | 6.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 19 | 19 | $5,795 | $1,596 | 27.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 13 | $3,120 | $1,260 | 40.4% |
About Dr. Alexander Perelman, D.O
Dr. Alexander Perelman, D.O is a Gastroenterology healthcare provider based in West Orange, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2014. The National Provider Identifier (NPI) number assigned to this provider is 1710399985.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander Perelman, D.O has received a total of $99,250 in payments from pharmaceutical and medical device companies, with $30,474 received in 2024. These payments were reported across 746 transactions from 31 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($73,809).
As a Medicare-enrolled provider, Perelman has provided services to 313 Medicare beneficiaries, totaling 425 services with total Medicare billing of $38,239. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location West Orange, NJ
- Active Since 05/22/2014
- Last Updated 10/27/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1710399985
Products in Payments
- DUPIXENT (Biological) $73,321
- VOQUEZNA (Drug) $9,233
- XIFAXAN (Drug) $2,491
- HUMIRA (Biological) $961.20
- SKYRIZI (Biological) $867.61
- STELARA (Biological) $785.99
- TRULANCE (Drug) $753.61
- ENTYVIO (Biological) $752.51
- RINVOQ (Biological) $591.39
- ZEPOSIA (Drug) $539.42
- DIFICID (Drug) $462.03
- Talicia (Drug) $421.29
- SUCRAID (Drug) $270.19
- Sucraid (Drug) $247.51
- CLENPIQ (Drug) $239.41
- XELJANZ (Drug) $194.73
- SUTAB (Drug) $177.98
- LINZESS (Drug) $176.44
- INJECTAFER (Drug) $160.41
- CREON (Drug) $144.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in West Orange
Robert Schuman, Md, MD
Gastroenterology — Payments: $44,812
Gastroenterology $44,812
Matthew Askin, M.d, M.D
Gastroenterology — Payments: $14,388
Gastroenterology $14,388
Dr. Lawrence Rosenthal, M.d, M.D
Gastroenterology — Payments: $11,431
Gastroenterology $11,431
Dr. Andrew Stefaniwsky, M.d, M.D
Gastroenterology — Payments: $6,822
Gastroenterology $6,822
William Sloan, M.d, M.D
Gastroenterology — Payments: $4,911
Gastroenterology $4,911
Dr. Robert Ruffini, M.d, M.D
Gastroenterology — Payments: $4,479
Gastroenterology $4,479